Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors

Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned

Read more at globenewswire.com